Cargando…
Is Cell-Free DNA Testing in Hepatocellular Carcinoma Ready for Prime Time?
Revamping the current biomarker landscape of hepatocellular carcinoma (HCC) with cell-free DNA (cfDNA) could improve overall outcomes. The use of commercially available cfDNA testing (also known as liquid biopsy) is limited by the low prevalence of targetable mutations and does not have any prognost...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531802/ https://www.ncbi.nlm.nih.gov/pubmed/37762533 http://dx.doi.org/10.3390/ijms241814231 |